Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ENC1
REST API REST API
Homo sapiens
ENC1 is differentially expressed in 343 experiments: 161 organism parts: amygdala, brain, ... (159 more);, 223 disease states: normal, colon carcinoma, ... (221 more);, 101 cell types 463 cell lines 61 compound treatments and 76 other conditions.
Synonyms KLHL37, NRPB, TP53I10, ENC-1, PIG10
Orthologs ENC1 (Gallus gallus)   ENSCING00000017000 (Ciona intestinalis)   Enc1 (Mus musculus)   ENC1 (Bos taurus)   ENSCING00000005649 (Ciona intestinalis)   enc1 (Danio rerio)   Enc1 (Rattus norvegicus)   enc1 (Xenopus laevis)   ENC1 (Canis familiaris)   (Compare orthologs)
InterPro Term BACK, Kelch_1, Kelch_2, BTB_POZ, BTB/POZ-like, Kelch-like_gigaxonin
Gene Ontology Term protein binding, cytoskeleton, cytoplasm, nuclear matrix, multicellular organismal development, nucleus, nervous system development, actin binding
UniProt Accession D6R9D7, Q53XS2, O14682, B4DS90, E9PFU0
Search EB-eye ENSG00000171617
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
457 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21612, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, ... (56 experiments)

Factor Value U/D Experiments
embryonic stem cell
3
E-MEXP-930, E-MEXP-2426, E-GEOD-2248
endothelial cell
1
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-3998, E-GEOD-96
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD8+ T cell
2
E-GEOD-6740, E-MTAB-25
centroblast
2
E-TABM-702, E-GEOD-15271
CD4+ T cell
2
3
E-MEXP-1600, E-GEOD-6740, E-MTAB-24, E-MTAB-25, E-AFMX-5 ... (5 experiments)
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-MEXP-2280, ... (65 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-GEOD-3726, E-MTAB-57, E-MTAB-62
glioblastoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-6014
lung adenocarcinoma
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231
control
1
3
E-GEOD-21912, E-GEOD-20295, E-GEOD-8121, E-GEOD-20168
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
217 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (40 experiments)

Factor Value U/D Experiments
none
6
10
E-GEOD-5741, E-TABM-782, E-MEXP-1958, E-GEOD-1805, E-GEOD-412, ... (16 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
ethanol
2
E-MEXP-2241, E-GEOD-3113
transforming growth factor beta
2
E-GEOD-1805, E-GEOD-1724
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
IL-13 (Homo sapiens)
1
E-GEOD-3183
55 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-19246, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2283, E-MEXP-958, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-1045, E-TABM-1029, E-MEXP-1996, E-GEOD-2466, ... (19 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-GEOD-837, ... (15 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

Media
studied in E-GEOD-21612

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1422, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.395 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM